Gilead Sciences BTLA Agonist Trial Halted, Acquisition Value Impaired Gilead discontinued its lead BTLA agonist. This drug targeted rheumatoid arthritis. It was acquired from MiroBio for $405M. The trial halt impacts pipeline value. Gilead Sciences has ceased development of its lead BTLA agonist, an unnamed candidate for rheumatoid arthritis. This Phase 2 trial discontinuation follows an internal portfolio review, indicating the drug did not meet efficacy or safety thresholds. The BTLA agonist was the primary asset from Gilead's $405 million acquisition of MiroBio in 2022, intended to bolster its immunology pipeline. This trial halt falls under standard FDA and EMA regulatory oversight for investigational new drugs. Gilead will formally notify regulatory bodies of the discontinuation, as required by 21 CFR 312.30. No specific EMA action was previously reported for this drug in the BrunoSan database. The company must now assess the remaining value of the MiroBio acquisition and potential write-downs. The discontinuation is a significant setback for Gilead's immunology ambitions and the BTLA agonist class. Competitors like Bristol Myers Squibb, also exploring BTLA agonists, may face increased scrutiny. This event underscores the high-risk nature of drug development, particularly for novel mechanisms. Gilead's next immunology pipeline update is expected by Q4 2026.